Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Department of Anaesthesiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Scand J Trauma Resusc Emerg Med. 2021 Feb 8;29(1):30. doi: 10.1186/s13049-021-00846-w.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), an emerging virus, has caused a global pandemic. Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has led to high hospitalization rates worldwide. Little is known about the occurrence of in-hospital cardiac arrest (IHCA) and high mortality rates have been proposed. The aim of this study was to investigate the incidence, characteristics and outcome of IHCA during the pandemic in comparison to an earlier period.
This was a retrospective analysis of data prospectively recorded during 3-month-periods 2019 and 2020 at the University Medical Centre Hamburg-Eppendorf (Germany). All consecutive adult patients with IHCA were included. Clinical parameters, neurological outcomes and organ failure/support were assessed.
During the study period hospital admissions declined from 18,262 (2019) to 13,994 (2020) (- 23%). The IHCA incidence increased from 4.6 (2019: 84 IHCA cases) to 6.6 (2020: 93 IHCA cases)/1000 hospital admissions. Median stay before IHCA was 4 (1-9) days. Demographic characteristics were comparable in both periods. IHCA location shifted towards the ICU (56% vs 37%, p < 0.01); shockable rhythm (VT/VF) (18% vs 29%, p = 0.05) and defibrillation were more frequent in the pandemic period (20% vs 35%, p < 0.05). Resuscitation times, rates of ROSC and post-CA characteristics were comparable in both periods. The severity of illness (SAPS II/SOFA), frequency of mechanical ventilation and frequency of vasopressor therapy after IHCA were higher during the 2020 period. Overall, 43 patients (12 with & 31 without COVID-19), presented with respiratory failure at the time of IHCA. The Horowitz index and resuscitation time were significantly lower in patients with COVID-19 (each p < 0.01). Favourable outcomes were observed in 42 and 10% of patients with and without COVID-19-related respiratory failure, respectively.
Hospital admissions declined during the pandemic, but a higher incidence of IHCA was observed. IHCA in patients with COVID-19 was a common finding. Compared to patients with non-COVID-19-related respiratory failure, the outcome was improved.
严重急性呼吸系统综合征冠状病毒 2 型(SARS-CoV-2)是一种新兴病毒,已导致全球大流行。由 SARS-CoV-2 引起的 2019 年冠状病毒病(COVID-19)导致全球住院率居高不下。目前尚不清楚院内心搏骤停(IHCA)的发生情况,据报道死亡率较高。本研究旨在调查大流行期间与早期相比 IHCA 的发生率、特征和结局。
这是对 2019 年和 2020 年在汉堡埃彭多夫大学医学中心(德国)连续 3 个月前瞻性记录的数据进行的回顾性分析。所有连续发生 IHCA 的成年患者均纳入研究。评估临床参数、神经结局和器官衰竭/支持情况。
在研究期间,住院人数从 2019 年的 18262 人下降至 2020 年的 13994 人(下降 23%)。IHCA 的发生率从 4.6/1000 人(2019 年:84 例 IHCA 病例)增加至 6.6/1000 人(2020 年:93 例 IHCA 病例)。IHCA 发生前的中位住院时间为 4(1-9)天。两个时期的人口统计学特征相似。IHCA 发生地点向 ICU 转移(56% vs 37%,p<0.01);可除颤节律(VT/VF)(18% vs 29%,p=0.05)和电除颤在大流行期间更常见(20% vs 35%,p<0.05)。复苏时间、ROSC 率和 CA 后特征在两个时期相似。2020 年期间,SAPS II/SOFA 严重程度、机械通气频率和 IHCA 后血管加压药治疗频率更高。总体而言,43 名患者(12 名患有 COVID-19 和 31 名无 COVID-19)在 IHCA 时存在呼吸衰竭。COVID-19 患者的 Horowitz 指数和复苏时间明显更低(均 p<0.01)。有 COVID-19 相关呼吸衰竭的患者和无 COVID-19 相关呼吸衰竭的患者的良好结局分别为 42%和 10%。
大流行期间住院人数下降,但 IHCA 的发生率升高。COVID-19 患者中 IHCA 是常见现象。与非 COVID-19 相关呼吸衰竭患者相比,结局得到改善。